3Pujol JL, Breton R, Gervais B, et al. Phase Ⅲ double - blind, placebo-controlled study of Thalidomide in extensive- disease small -cell lung cancer after response to chemotherapy:an intergroup study FNCLCC cleo04 -IF- CT 00 - 01 [ J 1. Clin Oncol,2007,25 (25) :3945-3951.
4Bagli E, Stefaniotou M, Morbidelli L. Luteolin inhibits vascular endothelial growth actor-induced angiogenesis;inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3 ' - kinase activity [ J ]. Cancer Research, 2004,64 ( 21 ) :7936-7946.
5Inoue M, Matsumoto S, Saito H, Tsujitani S, IkegucM M. Intraperitoneal administration of a small interfering RNA targeting nuclear factor - kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer [ J ]. Int J Cancer,2008,123 ( 11 ) : 2696- 2701.
6Taniguchi K, Momiyama N, Ueda M, Matsuyama R, Mori R,Fujii Y, Ichikawa Y, Endo I, Togo S, Shimada H. Targeting of CDC20 via small interfering RNA causes enhancement of the cytotoxicity of chemoradiation [ J ]. Anticancer Res,2008,28 (3A) : 1559-1564.
7Kuiper RAJ,Schellows JHM,Blijhan GH,et al.Clinical research on antiangiogenic therapy[J] Pharmocol Res,1998,37 (1):1-15.
8Rosen LS.VEGF-targeted therapy:thempeutie potential and recent advances[J].Oncologist,2005,10 (6):382-391.
9Burrows FJ,Watanabe Y,Thorpe PE,et al.Amurine model for antibody-derived targeting of vascular endothelial cells in solid tumors[J].Cancer Res,1992,52(21):5954-5959.
10Liu J,Razani B,Tang S,et al.Angiogenesis activators and inhibitoms differentially regulatate caveolin-1 expression and caveolate formation in vascular endothelial cells[J].J Biol Chem,1999,274(22):15781-15785.
